Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Sen. Kennedy Circulates Draft Of Health Reform Legislation
Senate Health, Education, Labor and Pensions Committee Chair Edward Kennedy (D-Mass.) is circulating an outline of health care overhaul legislation that includes a requirement that all individuals obtain coverage and requires contributions from employers, the Washington Post reports. According to the Post, the legislation "closely resembles" the Massachusetts health insurance law enacted in 2006, the Post reports. According to the draft summary, the bill calls for a public, government-sponsored health insurance option that would compete with private insurers. The measure also would expand Medicaid eligibility, according to the Post. Kennedy spokesperson Anthony Coley said that the outline is not yet finalized. He said, "We are still actively negotiating with members" of the Senate HELP Committee. According to a top White House official, Kennedy is expected to introduce his measure on Monday. A timetable released by Kennedy"s office calls for Senate HELP Committee Democrats to meet June 2 (Connolly, Washington Post, 5/29). A bipartisan walk-through of Kennedy"s bill is scheduled for June 5 and June 9. Hearings on the bill would then take place on June 10 or June 11. The mark up of the bill is scheduled from June 16 through June 25 (Bogardus, The Hill, 5/28). If Kennedy holds to the schedule, he will be ahead of other congressional Democrats, including Senate Finance Committee Chair Max Baucus (D-Mont.), on proposing overhaul legislation (Washington Post, 5/29). Coley said, "These are target dates that are not set in stone." Although Senate Democrats are hoping to pass health care reform legislation before the August recess, several senators have questioned whether that timeline is feasible (The Hill, 5/28). Reform Supporters Call For Removal of Ad

Deworming Drug Could Help Reduce Spread Of HIV In Africa, Study Finds
Providing girls in rural Africa with a deworming drug could help reduce the spread of HIV, according to a study recently published in PLoS Neglected Tropical Diseases, the New York Times reports. The drug, called praziquantel, costs about 32 cents per pediatric dose and prevents schistosomiasis, a worm disease that starts as a urinary tract infection. If untreated, schistosomiasis can lead to female genital sores that can facilitate HIV infection. Because the drug can kill the worms but cannot cure genital sores, girls should be protected before they reach sexual maturity, according to the Times. "For this relatively small investment, the reproductive health of young women would be improved," the authors from the Sabin Vaccine Institute, Imperial College London and Oslo University wrote, adding that "there is a reasonable chance that HIV/AIDS transmission can be reduced." There are about 207 million schistosomiasis cases worldwide, 90% of which occur in Africa, where humans are exposed usually through snail-infested water. According to a pilot program conducted in Burkina Faso, all 70 million cases among young children in Africa could be treated for $22 million, and repeating universal treatment every two years for 10 years would cost $112 million (McNeil, New York Times, 5/26).
News of the day
Hydrogen Peroxide In The Immune System
When you were a kid your mom poured it on your scraped finger to stave off infection. When you got older you might have even used it to bleach your hair. Now there"s another possible function for this over-the-counter colorless liquid: your body might be using hydrogen peroxide as an envoy that marshals troops of healing cells to wounded tissue.
Nutrition

Patient Upside Murky In Drug-Price Cases

"The prices of hundreds of brand-name drugs are about to be cut 4%, and millions of Americans may soon receive a check in the mail as compensation for having overpaid for their prescriptions," but "the extent to which the average consumer will benefit isn"t yet clear," the Wall Street Journal reports. "The price cuts and expected payments are the result of federal class-action settlements involving two drug-price publishers and a major drug wholesaler that were accused of inflating drug prices." The price rollbacks may save $100 billion in the first year, with about $100 million of that amount "saved directly by patients, while the balance would accrue to employers and private health insurers." But critics say that "because drug pricing is so opaque and complex, patients won"t likely get meaningful and long-lasting relief." Eighty-four million dollars may go to pay attorney fees, and pharmacies are still trying to stop the price rollbacks, "which could shrink their profit margins." In addition to price cuts, under the settlement, "uninsured patients who filled prescriptions for such widely used drugs as Pfizer Inc."s Lipitor, Sanofi Aventis SA"s Ambien and hundreds of other medicines between August 2001 and Jan. 23, 2009 are eligible for reimbursement checks from an about $60 million pot that has been set aside." According to testimony for the plaintiffs, the extra costs for insurers and patients comes to $2.9 billion. Many insured patients were also likely "affected indirectly because the higher costs added to a rise in health-insurance premiums." In order to qualify for the reimbursement funds, patients must have "kept good records" of their purchases and must submit claim forms by July 9 to a settlement administrator" (Rubenstein, 6/11). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009